This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08957/identifier/wikipedia/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB08957/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://www.drugs.com/international/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08957
rdf:type
n5:Drug
n5:description
Hexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.
n5:generalReferences
# Pinder RM, Brogden RN, Speight TM, Avery GS: Hexoprenaline: a review of its pharmacological properties and therapeutic efficacy with particular reference to asthma. Drugs. 1977 Jul;14(1):1-28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/195789
n5:group
approved withdrawn
owl:sameAs
n10:DB08957
dcterms:title
Hexoprenaline
adms:identifier
n12:Hexoprenaline n13:DB08957
n5:salt
n5:synthesisReference
U.S. Patent 3,329,709.
foaf:page
n4:hexoprenaline.html
n5:IUPAC-Name
n6:271B5FE0-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5FE6-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5FE5-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5FE2-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5FE3-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5FE4-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5FDE-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5FDC-363D-11E5-9242-09173F13E4C5 n6:271B5FDF-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5FDD-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:R03CC05 n8:R03AC06
n5:H-Bond-Acceptor-Count
n6:271B5FEC-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5FED-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5FE7-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5FE8-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5FEA-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5FE9-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5FEB-363D-11E5-9242-09173F13E4C5
n5:casRegistryNumber
3215-70-1
n5:Bioavailability
n6:271B5FF2-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5FF4-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5FF5-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5FF6-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5FF1-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5FF0-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5FF3-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5FE1-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5FEE-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5FEF-363D-11E5-9242-09173F13E4C5